COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,362 Articles (22,803 medRxiv, 8,559 bioRxiv)

Most recent first Previous |  Page 753: Articles 7521-7530  | Next

A single-component luminescent biosensor for the SARS-CoV-2 spike protein
Ravalin, M., Roh, H., Suryawanshi, R., Kumar, G. R., Pak, J. E., Ott, M., Ting, A. Y.
10.1101/2022.06.15.496006 — Posted: 2022-06-15
HIV skews the SARS-CoV-2 B cell response toward an extrafollicular maturation pathway
Krause, R., COMMIT-KZN Team, , Snyman, J., Hwa, S.-H., Muema, D., Karim, F., Ganga, Y., Ngoepe, A., Zungu, Y., Gazy, I., Bernstein, M., Khan, K., Mazibuko, M., Mthabela, N., Ramjit, D., Limbo, O., Jardine, J., Sok, D., Wilson, I. A., Hanekom, W., Sigal, A., Kloverpris, H., Ndung'u, T., Leslie, A.
10.1101/2022.06.14.496062 — Posted: 2022-06-15
Casirivimab and Imdevimab Treatment in Seropositive, Hospitalized COVID-19 Patients With Non-neutralizing or Borderline Neutralizing Antibodies
Hooper, A. T., Somersan-Karakaya, S. T., McCarthy, S. E., Mylonakis, E., Ali, S., Mei, J., Bhore, R., Mahmood, A., Geba, G. P., Dakin, P., Weinreich, D. M., Yancopoulos, G. D., Herman, G. A., Hamilton, J. D., the COVID-19 Phase 2/3 Hospitalized Trial Team
10.1101/2022.06.14.22276389 — Posted: 2022-06-14
Protective efficacy of COVAXIN(R) against Delta and Omicron variants in hamster model
Yadav, P., Mohandas, S., Shete, A., Sapkal, G., Deshpande, G., Kumar, A., Wakchaure, K., Dighe, H., Jain, R., Ganneru, B., Yemul, J., Gawande, P., Vadrevu, K. M., Abraham, P.
10.1101/2022.06.14.496021 — Posted: 2022-06-14
Antigenic escape accelerated by the presence of immunocompromised hosts
Kumata, R., Sasaki, A.
10.1101/2022.06.13.495792 — Posted: 2022-06-14
Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior protective humoral immune response to SARS-CoV-2
Taddeo, A., Berenguer Veiga, I., Devisme, C., Boss, R., Plattet, P., Weigang, S., Kochs, G., Thiel, V., Benarafa, C., Zimmer, G.
10.1101/2022.06.14.495413 — Posted: 2022-06-14
Clinical sensitivity and specificity of a high-throughput microfluidic nano-immunoassay combined with capillary blood microsampling for the identification of anti-SARS-CoV-2 Spike IgG serostatus
Michielin, G., Arefi, F., Puhach, O., Bellon, M., Sattonnet, P., L'Huillier, A., Eckerle, I., Meyer, B., Maerkl, S. J.
10.1101/2022.06.09.22276142 — Posted: 2022-06-14
Baseline Peripheral Blood Counts and Outcomes in Patients Presenting with COVID-19
Jeyaraman, P., Borah, P., Singh, O., Dewan, A., Dayal, N., Naithani, R.
10.1101/2022.06.10.22276256 — Posted: 2022-06-14
The evolving scenario of COVID-19 in hemodialysis patients
Esposito, P., Picciotto, D., Cappadona, F., Russo, E., Falqui, V., Conti, N. E., Parodi, A., Mallia, L., Cavagnaro, S., Battaglia, Y., Viazzi, F.
10.1101/2022.06.09.22276185 — Posted: 2022-06-14
Kidney patients remain at increased risk for succumbing to COVID-19
Hendrickx, R., Jellingso, M., Sommer, M. O. A.
10.1101/2022.06.12.22276220 — Posted: 2022-06-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).